Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515065 | 1.00 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL13637318 | 1.00 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL31572071 | 0.86 | SLC1A2 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL22418748 | 0.84 | GRIK1 (0.53) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL21585632 | 0.84 | GRIK1 (0.53) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL28611446 | 0.82 | GPR84 (0.55) | SLC1A2SLC1A1GRIK1GRIK2CYP3A4 | |
| SCHEMBL6760745 | 0.80 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL13883453 | 0.80 | SLC1A2 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL12464317 | 0.80 | CA1 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7076350 | 0.80 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080307585-A1 | Fluorescent whitening agent, for whitening synthetic or natural organic materials, especially paper and for the fluorescent whitening and improvement of sun protection factors of textile materials | CIBA SPECIALTY CHEMICALS CORP. | 2008-12-18 | — | — | US | claimed |
| US-7351808-B2 | Anionic monoazo dyes | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-04-01 | — | — | US | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | BONAC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20170306325-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR REGULATING EXPRESSION OF GENE HAVING DELIVERING FUNCTION | BONAC CORPORATION (JP) | 2017-10-26 | — | — | US | disclosed |
| US-8765910-B2 | Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20100311112-A1 | METHOD FOR AMIDATING POLYPEPTIDES WITH BASIC AMINO ACID C-TERMINALS BY MEANS OF SPECIFIC ENDOPROTEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-7595198-B2 | Photocleavable isotope-coded affinity tags | AMBERGEN, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| US-4296095-A | SALTS OF LYSINE ESTERS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | ZFX, ZFR, SRRT | CHRM1 4717/4885AKR1A1 1638/4885CHRM3 4597/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | CHRM1 4316/4885AKR1A1 2030/4885CHRM3 3480/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | CHRM1 4827/4885AKR1A1 2678/4885CHRM3 4838/4885 |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | IAPP, NPPA, ARG1 | CHRM1 1960/4885AKR1A1 4303/4885CHRM3 2306/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | CHRM1 4818/4885AKR1A1 2186/4885CHRM3 4825/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | CHRM1 3894/4885AKR1A1 3328/4885CHRM3 4024/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | CHRM1 4827/4885AKR1A1 18/4885CHRM3 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.